Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

787 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD

NCT00274053

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Boehringer Ingelheim Investigational Site Aix-les-Bains, France
  • Hôpital Privé Antony Antony, France
  • Boehringer Ingelheim Investigational Site Bordeaux, France
  • Boehringer Ingelheim Investigational Site Cambo-les-Bains, France
View all 27 locations
View Trial Details
Completed

Tiotropium (Spiriva) Rehabilitation Study

NCT00274521

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • Attention: John E. Hodgkin, M.D. Deer Park, California, United States
  • Boehringer Ingelheim Investigational Site Long Beach, California, United States
View all 19 locations
View Trial Details
Completed

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

NCT00239408

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Hospital Garcia de Orta Almada, Portugal
  • Hospital Fernando Fonseca Amadora, Portugal
  • Hospital Santo Espírito de Angra do Heroismo Angra Do Heroismo - Açores, Portugal
  • Hospital Infante D. Pedro Aveiro, Portugal
View all 33 locations
View Trial Details
Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00240435

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • Boehringer Ingelheim Investigational Site Downey, California, United States
  • University of California - Los Angeles Los Angeles, California, United States
  • Boehringer Ingelheim Investigational Site Palo Alto, California, United States
View all 25 locations
View Trial Details
Completed

Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva

NCT00274066

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Twenteborg Ziekenhuis Almelo, Netherlands
  • Amphia Ziekenhuis Breda, Netherlands
  • Boehringer Ingelheim Investigational Site Groningen, Netherlands
  • Afdeling longziekten Winschoten, Netherlands
View Trial Details
Completed

Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD

NCT00274040

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Chungnam National University Hospital Daejeon, South Korea
  • Jeonbuk National University Hospital Jeonju, South Korea
  • Jeonnam National University Hospital Kwangju, South Korea
  • Pusan University Hospital Pusan, South Korea
View all 18 locations
View Trial Details
Completed

High Dose Trial in COPD

NCT00128440

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Boehringer Ingelheim Investigational Site Lakewood, California, United States
  • Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
  • Boehringer Ingelheim Investigational Site Pembroke Farms, Florida, United States
  • Boehringer Ingelheim Investigational Site Coeur d'Alene, Idaho, United States
View all 13 locations
View Trial Details
Completed

A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00292448

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Boehringer Ingelheim Investigational Site Akita, Akita, Japan
  • Boehringer Ingelheim Investigational Site Bunkyo-ku, Tokyo, Japan
  • Boehringer Ingelheim Investigational Site Bunkyo-ku,Tokyo, Japan
  • Boehringer Ingelheim Investigational Site Habikino, Osaka, Japan
View all 27 locations
View Trial Details

Related conditions